Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology

Volumn 58, Issue 1, 2008, Pages 106-115

  Menter, Alan ^a   Tyring, Stephen K ^b   Gordon, Kenneth ^c   Kimball, Alexa B ^d   Leonardi, Craig L ^e   Langley, Richard G ^f   Strober, Bruce E ^g   Kaul, Martin ^h   Gu, Yihua ⁱ   Okun, Martin ⁱ   Papp, Kim ^j  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DALHOUSIE UNIVERSITY   (Canada)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ABBOTT GMBH AND CO KG   (Germany)

ⁱ ABBOTT LABORATORIES   (United States)

^j PROBITY MEDICAL RESEARCH   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; FLUCONAZOLE; FUROSEMIDE; ISONIAZID; PLACEBO;

ADULT; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX SCORE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SINUSITIS; THERAPY EFFECT; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349003068     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.09.010     Document Type: Article

References (18)

1. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., and Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (2001) 280-284
2. Finlay A.Y., and Coles E.C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132 (1995) 236-244
3. Rapp S.R., Feldman S.R., Exum M.L., Fleischer Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
4. Stern R.S., Nijsten T., Feldman S.R., Margolis D.J., and Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
5. Christophers E., Griffiths C.E., Gaitanis G., and van de Kerkhof P. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol 20 (2006) 921-925
6. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 (1993) 354-362
7. Calabrese L.H. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 21 (2003) 241-248
8. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
9. Fredriksson T., and Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157 (1978) 238-244
10. Ko H-S. Clinical trial design in psoriasis. Oral presentation at: 49th Meeting of the Dermatologic and Ophthalmologic Advisory Committee; March 20, 1998; Bethesda, MD.
11. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
12. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., Griffiths C.E., et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
13. Menter A., Gordon K., Carey W., Ortonne J.P., Roberts J., and Griffiths C.E. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
14. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005) 1367-1374
15. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the comparative study of adalimumab (Humira) versus mexotrexate versus placebo in psoriasis patients (CHAMPION). Br J Dermatol. In press.
16. Humira. [package insert] (2007), Abbott Laboratories, North Chicago, IL
17. Smith K.J., and Skelton H.G. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 45 (2001) 953-956
18. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical and functional outcomes with adalimumab (a human anti-TNF monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411